At an event in the Oval Office, federal officials said the changes could pave the way for such drugs — which can cause hallucinations and are largely illegal — to be reclassified if clinical trials prove successful. Trump also announced $50m in federal funding for ibogaine research. The commissioner of the FDA, Marty Makary, said decisions on the drug could come “as soon as this summer”.
